Press release
Familial Adenomatous Polyposis Pipeline Therapeutics Development Market Review 2017
Complete report on H1 2017 pipeline review of Familial Adenomatous Polyposis with 180 market data tables and 16 figures, spread across 39 pages is available at http://www.rnrmarketresearch.com/familial-adenomatous-polyposis-pipeline-review-h1-2017-market-report.html .
The report also reviews key players involved in the therapeutic development for Familial Adenomatous Polyposis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies discussed in this Familial Adenomatous Polyposis Pipeline Review, H1 2017 report include Cancer Prevention Pharmaceuticals Inc, Marina Biotech Inc, Thetis Pharmaceuticals LLC.
You Can Get Discount on This Report At http://www.rnrmarketresearch.com/contacts/discount?rname=918805 (This report is available at upto 25% Discount till 02 June 2017).
Drug Profiles Discussed In Report (celecoxib + lisinopril), (eflornithine hydrochloride + sulindac), CEQ-508, EM-011, pyrvinium pamoate, TP-252.
Familial adenomatous polyposis (FAP) is also known as familial polyposis coli, adenomatous polyposis coli, or Gardner syndrome. Familial adenomatous polyposis (FAP) is an inherited disorder characterized by cancer of the large intestine (colon) and rectum. People with the classic type of familial adenomatous polyposis may begin to develop multiple noncancerous (benign) growths (polyps) in the colon as early as their teenage years. Unless the colon is removed, these polyps will become malignant (cancerous). Symptoms may include bleeding from the rectum, change in bowel habits, abdominal pain, low blood counts or unexplained weight loss.
Familial Adenomatous Polyposis (Genetic Disorders) pipeline reviews of key players involved in therapeutic development for Familial Adenomatous Polyposis and features dormant and discontinued projects. The molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.
Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=918805 .
Scope of this report: The report provides a snapshot of the global therapeutic landscape of Familial Adenomatous Polyposis and reviews pipeline therapeutics for Familial Adenomatous Polyposis by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Familial Adenomatous Polyposis therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Familial Adenomatous Polyposis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Familial Adenomatous Polyposis.
List of Tables
Number of Products under Development for Familial Adenomatous Polyposis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Familial Adenomatous Polyposis - Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2017
Familial Adenomatous Polyposis - Pipeline by Marina Biotech Inc, H1 2017
Familial Adenomatous Polyposis - Pipeline by Thetis Pharmaceuticals LLC, H1 2017
Familial Adenomatous Polyposis - Dormant Projects, H1 2017
Familial Adenomatous Polyposis - Discontinued Products, H1 2017
About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel: +1-888-391-5441
sales@rnrmarketresearch.com
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel: +1-888-391-5441
sales@rnrmarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Familial Adenomatous Polyposis Pipeline Therapeutics Development Market Review 2017 here
News-ID: 549818 • Views: …
More Releases from RNR Market Research
Emerging Trends Exosome Diagnostics and Therapeutics Market Dominated by Evox Th …
An exosome diagnostic and therapeutic study approach represents the opportunity to expand and develop the liquid biopsy market, a growing sector in cancer diagnostics. Once they reach the recipient cells, cytoplasmic ingredients can alter their biology.
Access Sample Papers of Exosome Diagnostics and Therapeutics Market with 248 Pages and 6 Company Profiles Now at http://www.rnrmarketresearch.com/contacts/request-sample?rname=1529771 .
Growth in exosome diagnostic and therapeutic market in these regions attributes to the technological advancement in…
17.8% CAGR for Care Management Solutions Market - Regions Like North America and …
Key care management solutions market players are Allscripts Healthcare Solutions, Inc. (U.S.), TriZetto Corporation (U.S.), Phytel Inc. (U.S.), EXL Healthcare (U.S.), AxisPoint Health (U.S.), Wellcentive, Inc. (U.S.), Medecision, Inc. (U.S.), ZeOmega Inc. (U.S.), i2i Systems, Inc. (U.S.), HealthSmart Holdings, Inc. (U.S.), Pegasystems Inc. (U.S.), Epic Corporation Inc. (U.S.), and Harmony Information Systems, Inc. (U.S.)
Download Brochure of Care Management Solutions Market spread across 191 pages, Profiling 15 Companies and Supported with…
Global 5K Display Resolution Market: 2019 Industry Analysis, Size, Trends, Growt …
This report presents the worldwide 5K Display Resolution Market size (value, production and consumption), splits the breakdown (data status 2014-2018 and forecast to 2025), by manufacturers, region, type and application. This study also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter’s Five Forces Analysis.
Global 5K Display Resolution Market Report including definitions, classifications, applications and…
Dialyzers Market 2019-2025: Global Consumption Value, Sales and Key Companies Pr …
The global Dialyzers Market 2019 research is a professional and in-depth study on the current state of the industry and provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.
This report presents the worldwide Dialyzers Market size (value, production and consumption), splits the breakdown (data status 2014-2018 and forecast to 2025), by manufacturers, region, type and application. This study also analyzes the market status, market…
More Releases for Familial
Homozygous Familial Hypercholesterolemia (HoFH) Market Massive Growth opportunit …
Introduction
Homozygous Familial Hypercholesterolemia (HoFH) is a rare genetic lipid disorder characterized by extremely high low-density lipoprotein cholesterol (LDL-C) levels from birth, often exceeding 500 mg/dL. Caused by mutations in both alleles of the LDLR, APOB, or PCSK9 genes, HoFH leads to early-onset atherosclerosis, cardiovascular disease, and premature mortality if untreated.
Historically, management relied on lipid-lowering agents, LDL apheresis, and lifestyle modifications. However, the last decade has witnessed a paradigm shift with…
Familial Adenomatous Polyposis (FAP) Therapeutics- Pipeline Analysis 2018
Familial adenomatous polyposis (FAP) is a genetic disorder, characterized by the development of adenomatous colon polyps in the intestinal tract, resulting in colon cancer. The disease is diagnosed when more than 100 adenomatous colon polyps are developed in a person.
Download the sample report at: https://www.pharmaproff.com/request-sample/1025
A person with FAP is at a high risk of developing cancer of small intestines or stomach. This disease is categorized into three types including attenuated…
Heterozygous Familial Hypercholesterolemia (heFH) Therapeutics - Pipeline Analys …
Heterozygous familial hypercholesterolemia (HeFH) is an inherited genetic disorder that affects the body’s ability to control cholesterol. It is characterized by very high LDL (low density lipoprotein) cholesterol (above 190 for adults or above 160 for children) and family history of high cholesterol, heart disease or stroke.
Download the sample report @ https://www.pharmaproff.com/request-sample/1135
A very high level of LDL from birth leads to a twenty-fold increase in the risk of premature…
Familial Amyloid Cardiomyopathy Treatment Market Opportunity Analysis, 2018–20 …
Aggregation and deposition of mutant and wild-type transthyretin protein (TTR) in heart results in familial amyloid cardiomyopathy, which typically occur after age of 60. Familial amyloid cardiomyopathy is also known as hereditary cardiac transthyretin amyloidosis or hereditary amyloid cardiomyopathy. The protein transthyretin amyloid fibrils infiltrate the myocardium that leads to diastolic dysfunction from restrictive cardiomyopathy, which eventually result to heart failure. There are several mutation in TTR which are associated…
Familial Adenomatous Polyposis - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Familial Adenomatous Polyposis - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Familial Adenomatous Polyposis - Pipeline Review, H1 2017, provides an overview of the Familial Adenomatous Polyposis (Genetic Disorders) pipeline landscape.
Familial adenomatous polyposis (FAP) is also known as familial polyposis coli, adenomatous polyposis coli, or…
A Crown Jewel of Familial Integrated Advertising
In the communication business for 75 years: The Frankfurt WEFRA Werbeagentur GWA is celebrating its birthday. The recipe for success of the oldest German agency: Not to follow every trend, but to rely on experience and competence and still stay innovative.
Whilst many agency owners sold their companies to large international networks, the agency which is still in familial hands, relies on independance. The grand age for the fast moving communication…
